```
=>
Uploading C:\Program Files\Stnexp\Queries\10597022.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
   REGistRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



SAMPLE SEARCH INITIATED 13:39:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   256560 TO ITERATE

  0.8% PROCESSED     2000 ITERATIONS                              40 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      5101513 TO  5160887
PROJECTED ANSWERS:           98328 TO   106920

L2           40 SEA SSS SAM L1


L3          28 L2

=> s l3 and py<2003
```

```
      22984637 PY<2003
L4          15 L3 AND PY<2003

=> d 1-15 ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 84.60 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4   ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:1014580  CAPLUS
DOCUMENT NUMBER:          138:411244
TITLE:                    Preparation of N-ureidoalkylpiperidines as modulators
                          of CCR3 chemokine receptor activity for the prevention
                          of asthma and other allergic diseases
INVENTOR(S):              Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim,
                          Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Pharma Company, USA
SOURCE:                   U.S., 126 pp., Cont.-in-part of U.S. Ser. No. 466,442.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   17
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ----------------    ----   --------    --------------------     --------
     US 6525069           B1    20030225    US 2000-597400           20000621
     US 6331541           B1    20011218    US 1999-465288           19991217 <--
     US 6444686           B1    20020903    US 1999-466442           19991217 <--
     US 6525069           B1    20030225    US 2000-597400           20000621
     ZA 2001003756        A     20020509    ZA 2001-3756             20010509 <--
     US 20030013741       A1    20030116    US 2001-7172             20011023
     US 6521592           B2    20030218
     US 20030114489       A1    20030619    US 2002-180869           20020626
     US 6897234           B2    20050524
     US 20040002515       A1    20040101    US 2002-279416           20021024
     US 6875776           B2    20050405
     US 20040006107       A1    20040108    US 2002-279231           20021024
     US 6780857           B2    20040824
     US 20050096325       A1    20050505    US 2004-983367           20041108
     US 20050192291       A1    20050901    US 2004-21042            20041223
PRIORITY APPLN. INFO.:                       US 1998-112717P     P    19981218
                                             US 1999-161221P     P    19991022
                                             US 1999-466442      A2   19991217
                                             US 2000-597400      T0   20000621
                                             US 1999-161137P     P    19991022
                                             US 1999-161184P     P    19991022
                                             US 1999-161222P     P    19991022
                                             US 1999-465287      A3   19991217
                                             US 1999-465288      A3   19991217
                                             US 1999-465948      A3   19991217
                                             US 2002-180869      A1   20020626
                                             US 2002-279416      A1   20021024
GI
```



I

AB Title compds. [I; M, Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, K, L = CH2, CHR5, CHR6, CR6R6, CR5R6; ≥1 of J, K, L contains R5; Z = O, S, NR1a, CHCN, CHNO2, C(CN)2; R1a = H, alkyl, cycloalkyl, CN, NO2, etc.; E = (substituted) C3-6 carbocyclyl, methylenecarbocyclyl, ethylenecarbocyclyl, etc.; R1, R2 = H, alkyl, alkenyl, alkynyl; R3 = (substituted) alkyl, alkenyl, alkynyl; R4 = null, N-oxide, alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R5 = (substituted) alkylenecarbocyclyl, alkyleneheterocyclyl; R6 = alkyl, alkenyl, alkynyl, alkylcycloalkyl, perfluoroalkyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, CN, etc.; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, mercaptoalkyl, acylaminoalkyl, (substituted) phenylalkyl, etc.], were prepared as CCR3 modulators (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) and 3-cyanophenyl isocyanate were stirred 30 min. in THF to give N-3-cyanophenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 8 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of N-ureidoalkylpiperidines as modulators of CCR3 chemokine receptor activity for the prevention of asthma and other allergic diseases)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:984035 CAPLUS
DOCUMENT NUMBER: 136:410950
TITLE: Preparation of N-ureidoheterocyclylalkylpiperidines as modulators of CCR3 chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Pruitt, James R.; Wacker, Dean A.; Batt, Douglas G.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 485 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002525 A2		20020110	WO 2001-XB20989	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRIORITY APPLN. INFO.: US 2000-215215P 20000630
GI



I

AB Title compds. [I; M = null, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, K = CH2, CHR5, CHR6, CR6R6, CR5R6; L = CHR5, CR5R6; when M = null, J = CH2, CHR5, CHR13, CR5R13; Z = O, S, NR1a, C(CN)2, CH(NO2), CHCN; R1a = H, alkyl, cycloalkyl, CONR1bR1b, OR1b, CN, NO2, (alkyl)phenyl; R1b = H, alkyl, cycloalkyl, Ph; E = G(CHR')mB(CHR')m; G = bond, CO, SO2; B = (substituted) 5-7 membered saturated heterocyclyl; R1, R2 = H, alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, fluoroalkyl, haloalkyl, (alkyl)carbocyclyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R5 = (substituted) (alkyl)cycloalkyl, alkylheterocyclyl; R6 = alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl, etc.; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R' = H, alkyl, alkenyl, alkynyl, etc.; m = 0-2], were prepared as modulators of CCR3 chemokine receptor activity (no data). Thus, (3R,4R)-4-amino-3-[(S)-3-(4-fluorobenzyl)piperidine-1-carbonyl]piperidine-1-carboxylic acid tert-Bu ester (preparation given) in THF/Et3N was treated with 3-acetylphenyl isocyanate followed by stirring for 17 h to give 62% (3R,4R)-4-[3-(3-acetylphenyl)ureido]-3-[(S)-3-(4-fluorobenzyl)piperidine-1-carbonyl]piperidine-1-carboxylic acid tert-Bu ester. [This abstract record is one of 20 records for this document necessitated by the large number of

index entries required to fully index the document and publication system constraints.]

IT 1144668-00-7
RL: PRPH (Prophetic)
(Preparation of N-ureidoheterocyclylalkylpiperidines as modulators of CCR3 chemokine receptor activity)

RN 1144668-00-7 CAPLUS

CN Benzamide, 4-[[[[3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]carbonyl]-1-(2-oxopropyl)-4-piperidinyl]amino]carbonyl]amino]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:984034 CAPLUS

DOCUMENT NUMBER: 136:410949

TITLE: Preparation of N-ureidoheterocyclylalkylpiperidines as modulators of CCR3 chemokine receptor activity

INVENTOR(S): Ko, Soo S.; Pruitt, James R.; Wacker, Dean A.; Batt, Douglas G.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 485 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002525 A2		20020110	WO 2001-XA20989	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR
PRIORITY APPLN. INFO.: US 2000-215215P 20000630
GI



I

AB Title compds. [I; M = null, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, K = CH2, CHR5, CHR6, CR6R6, CR5R6; L = CHR5, CR5R6; when M = null, J = CH2, CHR5, CHR13, CR5R13; Z = O, S, NR1a, C(CN)2, CH(NO2), CHCN; R1a = H, alkyl, cycloalkyl, CONR1bR1b, OR1b, CN, NO2, (alkyl)phenyl; R1b = H, alkyl, cycloalkyl, Ph; E = G(CHR')mB(CHR')m; G = bond, CO, SO2; B = (substituted) 5-7 membered saturated heterocyclyl; R1, R2 = H, alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, fluoroalkyl, haloalkyl, (alkyl)carbocyclyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R5 = (substituted) (alkyl)cycloalkyl, alkylheterocyclyl; R6 = alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl, etc.; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R' = H, alkyl, alkenyl, alkynyl, etc.; m = 0-2], were prepared as modulators of CCR3 chemokine receptor activity (no data). Thus, (3R,4R)-4-amino-3-[(S)-3-(4-fluorobenzyl)piperidine-1-carbonyl]piperidine-1-carboxylic acid tert-Bu ester (preparation given) in THF/Et3N was treated with 3-acetylphenyl isocyanate followed by stirring for 17 h to give 62% (3R,4R)-4-[3-(3-acetylphenyl)ureido]-3-[(S)-3-(4-fluorobenzyl)piperidine-1-carbonyl]piperidine-1-carboxylic acid tert-Bu ester. [This abstract record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1159256-11-7
RL: PRPH (Prophetic)
(Preparation of N-ureidoheterocyclylalkylpiperidines as modulators of CCR3 chemokine receptor activity)

RN 1159256-11-7 CAPLUS

CN Benzamide, 4-[[[[1-(2-fluoroethyl)-2-[[3-[(3-fluorophenyl)methyl]-1-piperidinyl]carbonyl]-3-piperidinyl]amino]carbonyl]amino]-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:937766 CAPLUS
DOCUMENT NUMBER: 136:410947
TITLE: Preparation of piperidinoalkylureas as chemokine receptor modulators
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098270 A2		20011227	WO 2001-XG19752	20010620

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRIORITY APPLN. INFO.: US 2000-213208P 20000621
US 2000-597400 20000621

AB The title compds. were prepared as chemokine receptor modulators (no data). Thus, PhCH2Z(CH2)3NHR (Z = piperidine-4,1-diyl)(I; R = H)(preparation given) was amidated by 3-(NC)C6H4NCO to give I [R = CONHC6H4(CN)-3]. [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and

publication system constraints.]
IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of piperidinoalkylureas as chemokine receptor modulators)
RN 1069107-67-0 CAPLUS
CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:937751 CAPLUS
DOCUMENT NUMBER: 136:410933
TITLE: Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B.; Wacker, Dean A.; Yao, Wenqing
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA; Bristol-Myers Squibb Pharmaceutical Co.
SOURCE: PCT Int. Appl., 446 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098269 A2		20011227	WO 2001-XM19745	20010620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				
PRIORITY APPLN. INFO.:			US 2000-213051P	20000621
			US 2000-598821	20000621

GI



I

AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 15 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:461152 CAPLUS
DOCUMENT NUMBER: 135:211279
TITLE: Phosphinic Acid Pseudopeptides Analogous to Glutamyl-γ-glutamate: Synthesis and Coupling to Pteroyl Azides Leads to Potent Inhibitors of Folylpoly-γ-glutamate Synthetase
AUTHOR(S): Valiaeva, Nadya; Bartley, David; Konno, Tsutomu; Coward, James K.
CORPORATE SOURCE: Departments of Medicinal Chemistry and Chemistry, University of Michigan, Ann Arbor, MI, 48109-1055, USA
SOURCE: Journal of Organic Chemistry (2001), 66(15), 5146-5154
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:211279

AB Several routes to a complex phosphinate phosphapeptide analogous to the γ-glutamyl peptide Glu-γ-Glu have been investigated. Formation of γ-phosphono glutamate derivs. via addition of a phosphorus-based radical to protected vinylglycine was found to be of limited value because of the elevated temps. required. Alkylation and conjugate addition reactions of trivalent phosphorus (PIII) species were investigated. In situ generation of bis-trimethylsilyl esters of phosphinous acids proved to be an effective route to phosphinates of modest structural complexity. However, this chemical could not be extended to the incorporation of an amino acid moiety at the N-terminal side of the desired phosphinate. A successful synthesis of the target phosphinate phosphapeptide was effected using PIII chemical and dehydrohalogenation to yield an α,β-unsatd. phosphinic acid ester, following which conjugate addition of di-Et acetamidomalonate and acid-mediated hydrolysis afforded the desired phosphinate phosphapeptide. Coupling of the unprotected phosphinate phosphapeptide with two acyl azides derived from folic acid and methotrexate led to the corresponding pteroylphosphapeptides of interest as possible mimics of tetrahedral intermediates in the reaction catalyzed by folylpolyglutamate synthetase.

IT 357933-53-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of phosphinic acid pseudopeptides analogous to glutamyl-γ-glutamate and coupling to pteroyl azides leading to potent inhibitors of folylpoly-γ-glutamate synthetase)

RN 357933-53-0 CAPLUS
CN L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl](trifluoroacetyl)amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 42 THERE ARE 42 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:911769 CAPLUS
DOCUMENT NUMBER: 133:368977
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.; Watson, Paul S.; Varnes, Jeffrey G.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 394 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035451 A1		20000622	WO 1999-XN30332	19991217

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:		
US 1998-112717P		19981218
US 1999-161243P		19991022

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 17 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:911762 CAPLUS
DOCUMENT NUMBER: 133:368970
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo; Clark, Cheryl Mcardle; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035453 A1		20000622	WO 1999-XG30335	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1998-112717P	19981218
			US 1999-161137P	19991022

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

[This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2000:911754 CAPLUS
DOCUMENT NUMBER:	133:368962
TITLE:	Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S):	Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Gardner, Daniel S.
PATENT ASSIGNEE(S):	Du Pont Pharmaceuticals Company, USA
SOURCE:	PCT Int. Appl., 327 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035449 A1		20000622	WO 1999-XG30292	19991217

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:	US 1998-112717P	19981218
	US 1999-161122P	19991022

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:911744 CAPLUS
DOCUMENT NUMBER: 133:368952
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Duncia, John V. K.; Santella, Joseph B., III; Wacker, Dean A.; Kim, Ui Tae
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 351 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035454 A1		20000622	WO 1999-XN30336	19991217

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:	US 1998-112717P	19981218
	US 1999-161184P	19991022

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given.

Compds. I are effective at 1.0-20 mg/kg/da (oral dosage). [This abstract record is one of 17 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:911724 CAPLUS
DOCUMENT NUMBER: 133:368937
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. K.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035452 A1		20000622	WO 1999-XB30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1998-112717P 19981218
US 1999-161221P 19991022

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 1069107-67-0
RL: PRPH (Prophetic)
(Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 1069107-67-0 CAPLUS

CN Benzamide, 4-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-2-furanyl-3-[1-hydroxy-2-[3-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:148856 CAPLUS
DOCUMENT NUMBER: 126:157289
ORIGINAL REFERENCE NO.: 126:30415a
TITLE: Benzamide derivatives and their use as vasopressin antagonists
INVENTOR(S): Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi; Sato, Kentaro; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9641795	A1	19961227	WO 1996-JP1533	19960606	<--
W: AU, CA, CN, HU, IL, JP, KR, MX, NZ, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2223869	A1	19961227	CA 1996-2223869	19960606	<--
AU 9659110	A	19970109	AU 1996-59110	19960606	<--
EP 832061	A1	19980401	EP 1996-916324	19960606	<--
EP 832061	B1	20010905			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
CN 1192729	A	19980909	CN 1996-196175	19960606	<--
HU 9802694	A2	19990201	HU 1998-2694	19960606	<--
HU 9802694	A3	19990329			
JP 11508244	T	19990721	JP 1996-502896	19960606	<--
AT 205185	T	20010915	AT 1996-916324	19960606	<--
ES 2159738	T3	20011016	ES 1996-916324	19960606	<--
JP 4042160	B2	20080206	JP 1997-502896	19960606	
ZA 9604895	A	19961212	ZA 1996-4895	19960607	<--
US 6054457	A	20000425	US 1997-973103	19971209	<--
GR 3036881	T3	20020131	GR 2001-401746	20011011	<--
JP 2008074855	A	20080403	JP 2007-259213	20070904	

PRIORITY APPLN. INFO.:			
	GB 1995-11694	A	19950609
	JP 1997-502896	A3	19960606
	WO 1996-JP1533	W	19960606

OTHER SOURCE(S): MARPAT 126:157289
GI



I



II

AB The invention relates to new benzamide derivs. having vasopressin antagonistic activity, and to pharmaceutically acceptable salts thereof, processes for their preparation, and pharmaceutical compns. The compds. are represented by formula I [R1 = (un)substituted aryl, cycloalkyl, heterocyclyl; R2 = H, (un)substituted alkyl, cycloalkyl; R3 = H, halo, OH, (un)substituted acyloxy, alkyl, (cyclo)alkoxy, NO2, amino, acyl; R4 = OH, halo, NO2, (un)substituted amino, acyloxy, alkoxy, alkylthio, alk(en/yn)yl, etc; R5 = H, alkyl, alkoxy, halo; A = bond, O, NH; E = alkylene, alkenylene, CO, SO2, etc.; X = CH:CH, CH:N, S; Y = CH, N]. Approx. 470 synthetic examples of I and over 100 intermediates are described. For instance, amidation of 2-(PhCH2O)C6H4CO2H with 4-H2NC6H4CONMeC6H4[O(CH2)5CO2Et]-2 (preparation given), followed by saponification of the ester, amidation with N-methylpiperazine, hydrogenolytic debenzylation, etherification with N-(3-bromopropyl)phthalimide, hydrazinolyis of the imide, and acidification, gave title compound II as the di-HCl salt (III). In assays for binding at human vasopressin V1 receptors and cloned human V2 receptors in vitro, III had IC50 values of 14 and 1400 nM, resp.

IT 186657-09-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide derivs. as vasopressin antagonists)

RN 186657-09-0 CAPLUS

CN Benzamide, 3-methoxy-4-[[2-[[3-[(4-methoxyphenyl)methoxy]propyl]thio]benzoyl]amino]-N-methyl-N-[4-methyl-2-

[[6-(4-methyl-1-piperazinyl)-6-oxohexyl]oxy]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:708296 CAPLUS
DOCUMENT NUMBER: 125:328306
ORIGINAL REFERENCE NO.: 125:61495a,61498a
TITLE: Preparation of benzamide derivatives as vasopressin antagonists
INVENTOR(S): Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Hemmi, Keiji; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 281 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9529152	A1	19951102	WO 1995-JP788	19950421 <--
W: AU, CA, CN, JP, KR, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9522674	A	19951116	AU 1995-22674	19950421 <--
EP 757670	A1	19970212	EP 1995-916028	19950421 <--
EP 757670	B1	19990113		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09512528	T	19971216	JP 1995-527525	19950421 <--
JP 3845869	B2	20061115		
AT 175661	T	19990115	AT 1995-916028	19950421 <--
ES 2127524	T3	19990416	ES 1995-916028	19950421 <--
US 6211242	B1	20010403	US 1998-722243	19980130 <--

PRIORITY APPLN. INFO.: GB 1994-8185 A 19940425
WO 1995-JP788 W 19950421

OTHER SOURCE(S): MARPAT 125:328306
GI



I



II

AB Title compds. [I; (cyclo)alkyl, aryl, heterocyclyl, etc.; R2 = (cyclo)alkyl, arylalkyl, etc.; R3 = H, halo, alkyl, alkoxy, etc.; R4 = alkyl, (un)substituted aryl; X,Y = CH or N] were prepared Thus, PhNHMe was amidated by 4-(O2N)C6H4COCl and the reduced product amidated by 4-MeC6H4C6H4(CO2H)-2 to give title compound II. Data for in vitro vasopressin antagonism by I were given.

IT 183491-98-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide derivs. as vasopressin antagonists)

RN 183491-98-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[methyl[4-[[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]benzoyl]amino]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:849158 CAPLUS
DOCUMENT NUMBER: 123:256522
ORIGINAL REFERENCE NO.: 123:45879a,45882a
TITLE: Preparation of amide group-containing compounds as antithrombotics
INVENTOR(S): Himmelsbach, Frank; Linz, Guenter; Pieper, Helmut; Austel, Volkhard; Mueller, Thomas; Weisenberger, Johannes; Guth, Brian
PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4326344	A1	19950209	DE 1993-4326344	19930805 <--
EP 638553	A1	19950215	EP 1994-111620	19940726 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2129374	A1	19950206	CA 1994-2129374	19940803 <--
JP 07179424	A	19950718	JP 1994-183292	19940804 <--

PRIORITY APPLN. INFO.: DE 1993-4326344 A 19930805
OTHER SOURCE(S): CASREACT 123:256522; MARPAT 123:256522
GI



I

AB R1Z1Z2ZZ3Z4R4 [R1 = (un)substituted (di)azacycloalkyl, pyridyl; R4 = CO2H, alkoxycarbonyl, SO2H, tetrazolyl, etc.; Z = COZ5, Z5CO, Z5CONH, NHCOZ5, etc.; Z1 = bond, alk(en)ylene, O, S, NH, etc.; Z2 = (un)substituted phenylene, cycloalkylene, etc.; Z3 = alk(en)ylene, phenylene, etc.; Z4 = bond, OZ5, SO0-2Z5, NHZ5, etc.; Z5 = alkylene] were prepared Thus, quinuclidine was condensed with the ylide from 3-(Ph3P+H2C)C6H4CO2Me Br- and the reduced and saponified product condensed with Me trans-4-aminocyclohexanecarboxylate to give title compound trans-I.HCl (R = Me, R2 = 4-quinuclidinylethyl, R3 = H). Trans-I.HCl (R = R2 = H, R3 = 4-quinuclidinylmethoxy) had IC50 of 85nM against BIBU 52 binding at human thrombocytes in vitro.

IT 168891-81-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide group-containing compds. as antithrombotics)

RN 168891-81-4 CAPLUS

CN β-Alanine, N-[4-[[(4-aminocyclohexyl)carbonyl]amino]benzoyl]-, methyl ester, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1975:113179 CAPLUS
DOCUMENT NUMBER: 82:113179
ORIGINAL REFERENCE NO.: 82:18091a,18094a
TITLE: Fiber-reactive azo dyes
INVENTOR(S): Yamada, Yasushi; Ohno, Hiroaki
PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd.
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
DE 2425307	A1	19741212	DE 1974-2425307		19740524	<--
DE 2425307	C2	19840530				
JP 50007817	A	19750127	JP 1973-57691		19730525	<--
JP 57014390	B	19820324				
FR 2230694	A1	19741220	FR 1974-17952		19740522	<--
CH 609365	A5	19790228	CH 1974-7083		19740522	<--
GB 1471737	A	19770427	GB 1974-23362		19740524	<--
CH 616176	A5	19800314	CH 1978-6588		19780616	<--
PRIORITY APPLN. INFO.:			JP 1973-57691	A	19730525	
			CH 1974-7083	A	19740522	

GI For diagram(s), see printed CA Issue.
AB Reactive azo dyes I (3-SO3Na; R = 4-NHCOCBr:CH2)(II) [54633-16-8] and I (4-SO3Na; R = 3-NHCOCBr:CH2)(III) [54575-03-0] were prepared and used for dyeing wool light-, wash-, and perspirationfast red shades. Thus, successive reaction of 2,4-(H2N)2C6H3SO3H [88-63-1] with ClCH2COCl [79-04-9], diazotization, coupling with 1-[4-(α-bromoacrylamido)benzamido]-8-hydroxynaphthalene-3,6-disulfonic acid [54575-04-1], and salting gave II. Reaction of I (4-SO3Na; R = 3-NH2) [54575-01-8] with CH2BrCHBrCOCl [18791-02-1] followed by reaction with NaOH 15-20 min at 10-15° and pH 11-12 gave III.
IT 54575-04-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling of, with diazotized aminobenzenesulfonic acid derivative)
RN 54575-04-1 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 4-[[4-[(2-bromo-1-oxo-2-propen-1-yl)amino]benzoyl]amino]-5-hydroxy-, sodium salt (1:2) (CA INDEX NAME)



●2 Na

=> file stnguide